News tagged with erbitux
Cetuximab
Cetuximab (IMC-C225—marketed under the name Erbitux) is a chimeric (mouse/human) monoclonal antibody, an epidermal growth factor receptor (EGFR) inhibitor, given by intravenous infusion for treatment of metastatic colorectal cancer and head and neck cancer.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
Higher prices for MS drug help drug firm Merck
(AP)—Higher prices for its multiple sclerosis drug Rebif helped German pharmaceutical and high-tech materials company Merck KGaA post a 54 percent rise in first-quarter profit.
Other
May 14, 2013 |
not rated yet |
0
Merck Q4 net profit more than doubles
Merck KGaA saw its profit more than double in the fourth quarter as the German pharmaceutical company benefited from higher prices for its Rebif multiple sclerosis drug and reaped rewards from its ongoing restructuring.
Other
Mar 07, 2013 |
2 / 5 (1) |
0
Scientists find a new way to boost common cancer drugs
Shutting down a specific pathway in cancer cells appears to improve the ability of common drugs to wipe those cells out, according to new research from scientists at Fox Chase Cancer Center, published in the January issue ...
Cancer
Jan 14, 2013 |
5 / 5 (2) |
0
|
Merck KGaA suffers setback for cancer drug
German pharmaceuticals maker Merck KGaA said Tuesday it is withdrawing its application for its drug Erbitux to be used to treat patients with lung cancer.
Cancer
Sep 18, 2012 |
not rated yet |
0
New test helps evaluate cancer drug's merit
(HealthDay) -- A new genetic test to help doctors determine if the drug Erbitux would be an effective treatment for certain colorectal cancer patients has been approved by the U.S. Food and Drug Administration.
Cancer
Jul 09, 2012 |
not rated yet |
0
Merck KGaA suffers setback on cancer drug
German pharmaceuticals maker Merck KGaA said Thursday that phase III clinical trials of its gastric cancer drug Erbitux had shown no benefits for patients.
Cancer
Jul 05, 2012 |
not rated yet |
0
Test helps reduce risk of death in advanced lung cancer
Researchers at the University of Colorado Cancer Center have developed a test that identifies key biomarkers in advanced lung cancer that helped reduce the risk of death by 36 percent over a 30- month period in a recent clinical ...
Cancer
Oct 11, 2011 |
not rated yet |
0
Researchers link genetic marker to rectal cancer treatment
A team of researchers led by Keck School of Medicine of the University of Southern California (USC) oncologist Heinz-Josef Lenz, M.D., has identified a genetic marker that may predict which patients with rectal cancer can ...
Cancer
Jul 06, 2011 |
not rated yet |
0
|
High EGFR expression a predictor for improved survival with cetuximab plus chemotherapy
High epidermal growth factor receptor (EGFR) expression was a good predictor of which lung cancer patients would survive longer when cetuximab (Erbitux) was added to first-line chemotherapy, according to research presented ...
Cancer
Jul 05, 2011 |
not rated yet |
0
